|
August 10, 2010 VCA Oso Creek Animal Hospital completes its six month animal clinical trials using Plasma Technologies, Inc. Nitric Oxide Plasma device.
Corpus Christi (August 10th, 2010) - Plasma Technologies, Inc., a Texas corporation in cooperation with VCA Oso Creek Animal Hospital in Corpus Christi, Texas recently completed a six month animal clinical beta trial. PTI's PLASON® Thermal Plasma Nitric Oxide wound healing technology was used to treat six different small animals with severe, life-threatening traumatic wounds that were resistant to antibiotic therapy and difficult to treat by normal means. In all six cases, the PLASON® therapy helped control infection, including MRSA, and dramatically speeded healing rates.
"This third party beta trail helps affirm that PTI's PLASON® technology is able to control infections on living tissue, including difficult infections such as MRSA, and to promote quicker healing of living tissue as well, " said Bert Quintanilla, Plasma Technologies, Inc.'s VP of Community and Governmental Relations. "
The beta trial was supervised by Pam Pruitt, DVM, at VCA Oso Creek Animal Hospital in Corpus Christi. A copy of the beta trial results may be made available under certain conditions.
About VCA Oso Creek Animal Hospital:
VCA OSO Creek Animal Hospital is a full-service veterinary clinic offering 24-hour emergency care and Mobile Veterinary Service. Oso Creek has a staff of six veterinarians and specializes in small animal care and works with the Texas State Aquarium in the treatment of injuries to exotic animals
Forward Looking Statements:
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential and statements regarding future performance. Forward-looking statements are generally identified by the words "expects", "anticipates", "believes", "intends", "estimates", "plans" and similar expressions. Although Plasma Technologies, Inc. management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Plasma Technologies, Inc., that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA, regarding whether and when to approve any device or biological application that may be filed for any such product candidates as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of such products candidates, the absence of guarantee that the products candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, and the Company's ability to benefit from external growth opportunities. Other than as required by applicable law, Plasma Technologies, Inc. does not undertake any obligation to update or revise any forward-looking information or statements.
####
Bert Quintanilla, Plasma Technologies, Inc., 361-533-4815 bertq@ptimed.com
Dr. Pam Pruitt, VCA Oso Creek Animal Hospital, 361-994-1145 drpamprewitt@msn.com
|
|
